DECISION
Granting Patent Owner’s Motion to Expunge
37 C.F.R. §§ 42.14, 42.56 | Jul 30, 2019 | PAPER | BOARD |
Patent Owners Motion to Expunge Under 37 C.F.R. 42.56 | Jul 16, 2019 | PAPER | PATENT OWNER |
Patent Owner's Notice of Appeal | Dec 19, 2018 | PAPER | PATENT OWNER |
Decision Denying Patent Owner's Request for Rehearing | Dec 3, 2018 | PAPER | BOARD |
Panel Change Order | Sep 28, 2018 | PAPER | BOARD |
Patent Owners Request for Rehearing | Feb 16, 2018 | PAPER | PATENT OWNER |
Final Written Decision | Jan 17, 2018 | PAPER | BOARD |
EXPUNGED | Jan 17, 2018 | PAPER | BOARD |
Record of Oral Hearing | Jun 27, 2017 | PAPER | BOARD |
Patent Owners Reply in Support of its Motion to Exclude Evidence Pursuant to 37 C.F.R. 42.64(c) | May 17, 2017 | PAPER | PATENT OWNER |
Reply In Support of Petitioners' Motion to Exclude | May 17, 2017 | PAPER | PETITIONER |
Trial Hearing
37 C.F.R. sec 42.70 | May 15, 2017 | PAPER | BOARD |
Opposition to Motion for Observations | May 10, 2017 | PAPER | PETITIONER |
Garnick Declaration | May 10, 2017 | EXHIBIT | PETITIONER |
Petitioners' Fifth Updated Exhibit List | May 10, 2017 | PAPER | PETITIONER |
Petitioners' Opposition to Patent Owner's Motion to Exclude | May 10, 2017 | PAPER | PETITIONER |
Hoffman Declaration 5/10/17 | May 10, 2017 | EXHIBIT | PETITIONER |
Beel Declaration | May 10, 2017 | EXHIBIT | PETITIONER |
Hofmann Declaration 2/8/17 | May 10, 2017 | EXHIBIT | PETITIONER |
McKeague Deposition Exhibit 1146 | May 10, 2017 | EXHIBIT | PETITIONER |
Patent Owners Opposition to Petitioners Motion to Exclude Evidence Under 37 C.F.R. 42.64(c) | May 10, 2017 | PAPER | PATENT OWNER |
Petitioners' Response to Patent Owner¿¿¿s Identification of New Arguments & Request for Oral Argument | May 8, 2017 | PAPER | PETITIONER |
Patent Owners Identification of New Arguments and Evidence in Petitioners Reply | May 3, 2017 | PAPER | PATENT OWNER |
Patent Owners Request for Oral Argument | May 3, 2017 | PAPER | PATENT OWNER |
Petitioners' Request for Oral Hearing | May 3, 2017 | PAPER | PETITIONER |
Updated Counsel Information | May 3, 2017 | PAPER | PETITIONER |
Patent Owners Motion for Observations on Cross-Examination | May 3, 2017 | PAPER | PATENT OWNER |
Janssen Oncology, Inc.¿¿¿s Updated Exhibit List | May 3, 2017 | PAPER | PATENT OWNER |
JSN 2182 Marked up version of Exhibit C to Bantle declaration ¿¿¿ abiraterone acetate | May 3, 2017 | EXHIBIT | PATENT OWNER |
JSN 2183 Knol et al., ¿¿¿The Mis-use of Overlap of Confidence Intervals to Assess Effect Modification,¿¿¿ Eur. J. Epidemiol., 26:253-254 (2011) | May 3, 2017 | EXHIBIT | PATENT OWNER |
JSN 2185 Deposition Transcript of Marc B. Garnick, taken by Patent Owner on April 24, 2017 | May 3, 2017 | EXHIBIT | PATENT OWNER |
JSN 2187 Deposition Transcript of Ivan T. Hofmann, taken by Patent Owner on April 26, 2017 | May 3, 2017 | EXHIBIT | PATENT OWNER |
Patent Owners Motion to Exclude Evidence Pursuant to 37 C.F.R. 42.64(C) | May 3, 2017 | PAPER | PATENT OWNER |
JSN 2163 Sonino, NEJM, 217(13):812-818 (1987) | May 3, 2017 | EXHIBIT | PATENT OWNER |
JSN 2180 Marked up version of Exhibit C to Bantle declaration ¿¿¿ketoconazole | May 3, 2017 | EXHIBIT | PATENT OWNER |
JSN 2181 Marked up version of Exhibit C to Bantle declaration ¿¿¿ aminoglutethimide | May 3, 2017 | EXHIBIT | PATENT OWNER |
JSN 2184 Austin and Hux, ¿¿¿A Brief note on overlapping confidence intervals,¿¿¿ J. of Vascular Surgery, 36(1):194-195 (2002) | May 3, 2017 | EXHIBIT | PATENT OWNER |
JSN 2186 Deposition Transcript of Ian McKeague, taken by Patent Owner on April 28, 2017 | May 3, 2017 | EXHIBIT | PATENT OWNER |
JSN 2188 Deposition Transcript of John Bantle, taken by Patent Owner on April 24, 2017 | May 3, 2017 | EXHIBIT | PATENT OWNER |
Donovan Email (4-4-17) | May 3, 2017 | EXHIBIT | PETITIONER |
Petitioners' Motion to Exclude | May 3, 2017 | PAPER | PETITIONER |
Munoz Email | May 3, 2017 | EXHIBIT | PETITIONER |
Donovan Email (3-9-17) | May 3, 2017 | EXHIBIT | PETITIONER |
Petitioners' Fourth Updated Exhibit List | May 3, 2017 | PAPER | PETITIONER |
Order - 37 C.F.R. 42.5 | Apr 28, 2017 | PAPER | BOARD |
Patent Owners Objections to Evidence | Apr 26, 2017 | PAPER | PATENT OWNER |
Patent Owners Notice of Deposition of Marc B. Garnick, M.D. | Apr 21, 2017 | PAPER | PATENT OWNER |
Patent Owners Notice of Deposition of Ian McKeague, Ph.D. | Apr 21, 2017 | PAPER | PATENT OWNER |
Patent Owners Notice of Deposition of Ivan T. Hofmann CPA/CFF, CLP | Apr 21, 2017 | PAPER | PATENT OWNER |
Patent Owner¿¿¿s Notice of Deposition of John Bantle, M.D. | Apr 21, 2017 | PAPER | PATENT OWNER |
Decision Granting Motion for Pro Hac Vice Admission | Apr 20, 2017 | PAPER | BOARD |
DECISION Motion for Pro Hac Vice Admission | Apr 19, 2017 | PAPER | BOARD |
Updated Counsel Information | Apr 19, 2017 | PAPER | PETITIONER |
Potter 1995 | Apr 19, 2017 | EXHIBIT | PETITIONER |
BTG Press Release | Apr 19, 2017 | EXHIBIT | PETITIONER |
Zytiga Website | Apr 19, 2017 | EXHIBIT | PETITIONER |
Hormone Therapy for Prostate Cancer (cancer.org) | Apr 19, 2017 | EXHIBIT | PETITIONER |
COUAAOO1 Synopsis from Clinicaltrials.gov | Apr 19, 2017 | EXHIBIT | PETITIONER |
Arlt 2003 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Oelkers 1996 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Fossa 2001 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Osoba 1999 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Auchus 2014 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Luthy 1988 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Garnick 1989 | Apr 19, 2017 | EXHIBIT | PETITIONER |
PO Response | Apr 19, 2017 | EXHIBIT | PETITIONER |
Metastatic Cancer (cancer.org) | Apr 19, 2017 | EXHIBIT | PETITIONER |
PSA Test (cancer.org) | Apr 19, 2017 | EXHIBIT | PETITIONER |
Reid 2010 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Trump 1989 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Kruit 2004 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Ponder 1984 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Labrie 1989 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Berry 2002 | Apr 19, 2017 | EXHIBIT | PETITIONER |
De Coster 1987 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Figg 2005 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Chang 1989 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Goodman 2001 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Small 1997 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Small 1987 | Apr 19, 2017 | EXHIBIT | PETITIONER |
COUAABE Synopsis from clinicaltrials.gov | Apr 19, 2017 | EXHIBIT | PETITIONER |
Arinc 1991 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Wilson 2007 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Sartor 1998 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Collette 2006 | Apr 19, 2017 | EXHIBIT | PETITIONER |
FDA Prostate Cancer Endpoints Workshop | Apr 19, 2017 | EXHIBIT | PETITIONER |
Collette 2005 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Halabi 2013 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Scher 2008 | Apr 19, 2017 | EXHIBIT | PETITIONER |
US Patent No. 7,709,517 | Apr 19, 2017 | EXHIBIT | PETITIONER |
US Patent No. 9,126,941 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Taxotere Label (2004) | Apr 19, 2017 | EXHIBIT | PETITIONER |
Vellturo Amerigen Deposition Transcript | Apr 19, 2017 | EXHIBIT | PETITIONER |
FDA Taxotere Letter | Apr 19, 2017 | EXHIBIT | PETITIONER |
US Patent No. 8,183,274 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Orange Book - Xtandi | Apr 19, 2017 | EXHIBIT | PETITIONER |
Jevtana Label | Apr 19, 2017 | EXHIBIT | PETITIONER |
Taxotere Label (2015) | Apr 19, 2017 | EXHIBIT | PETITIONER |
J&J Press Release | Apr 19, 2017 | EXHIBIT | PETITIONER |
Judson Deposition Transcript | Apr 19, 2017 | EXHIBIT | PETITIONER |
Rettig Deposition Transcript | Apr 19, 2017 | EXHIBIT | PETITIONER |
Vellturo April 2017 Deposition Transcript | Apr 19, 2017 | EXHIBIT | PETITIONER |
Bantle Declaration | Apr 19, 2017 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 19, 2017 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 19, 2017 | EXHIBIT | PETITIONER |
Petitioners'' Third Updated Exhibit List | Apr 19, 2017 | PAPER | PETITIONER |
Garnick Reply Declaration | Apr 19, 2017 | EXHIBIT | PETITIONER |
Attard 2012 | Apr 19, 2017 | EXHIBIT | PETITIONER |
McKeague Reply Declaration | Apr 19, 2017 | EXHIBIT | PETITIONER |
Redacted Auchus Deposition Transcript | Apr 19, 2017 | EXHIBIT | PETITIONER |
Redacted Hofmann Reply Declaration | Apr 19, 2017 | EXHIBIT | PETITIONER |
Petitioners' Reply Brief | Apr 19, 2017 | PAPER | PETITIONER |
Motion to Seal | Apr 19, 2017 | PAPER | PETITIONER |
ERRATUM (IPR2017-00853) | Apr 13, 2017 | PAPER | BOARD |
DECISION - Institution of Inter Partes Review and Grant of Motion for Joinder (IPR2017-00853) | Apr 12, 2017 | PAPER | BOARD |
Motion for Pro Hac Vice Admission of Robert Swanson | Apr 4, 2017 | PAPER | PETITIONER |
Swanson PHV Declaration | Apr 4, 2017 | EXHIBIT | PETITIONER |
Second Auchus Depo Notice | Apr 3, 2017 | PAPER | PETITIONER |
Second Judson Depo Notice | Apr 3, 2017 | PAPER | PETITIONER |
Second Vellturo Depo Notice | Apr 3, 2017 | PAPER | PETITIONER |
Janssen Oncology, Inc.s Motion for Pro Hac Vice Admission of Alyssa B. Monsen | Apr 3, 2017 | PAPER | PATENT OWNER |
JSN 2159 Declaration of Alyssa B. Monsen | Apr 3, 2017 | EXHIBIT | PATENT OWNER |
Decision - Motion for Pro Hac Vice Admission - 37 CFR 42.10(c) | Mar 30, 2017 | PAPER | BOARD |
Second Rettig Deposition Notice | Mar 29, 2017 | PAPER | PETITIONER |
Motion for Pro Hac Vice Admission of Shannon M. Bloodworth | Mar 27, 2017 | PAPER | PETITIONER |
Bloodworth Declaration | Mar 27, 2017 | EXHIBIT | PETITIONER |
Rettig Deposition Notice | Mar 24, 2017 | PAPER | PETITIONER |
Judson Deposition Notice | Mar 24, 2017 | PAPER | PETITIONER |
Vellturo Deposition Notice | Mar 24, 2017 | PAPER | PETITIONER |
Auchus Deposition Notice | Mar 24, 2017 | PAPER | PETITIONER |
Auchus Deposition Notice | Mar 16, 2017 | PAPER | PETITIONER |
Objections to Patent Owner Evidence | Mar 15, 2017 | PAPER | PETITIONER |
Redline of Standing Protective Order | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2006 Hoffman Deposition Ex. 1 - J&J 2015 4th Q results | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2008 Hoffman Deposition Ex. 3 - Concordia v. Method | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
Motion to Seal Under 37 C.F.R. 42.14 and 42.54 | Mar 8, 2017 | PAPER | PATENT OWNER |
Standing Protective Order | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2007 Hoffman Deposition Ex. 2 - J&J 2016 4th Q results | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2013 Boehringer-Ingelheim-BTG Press Release | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2016 Danila et al., ¿¿¿Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2017 Ryan et al., ¿¿¿Phase II Study of Abiraterone in Chemotherapy-Na¿¿ve Flare Discordant with Serologic Response | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2018 Jubelirer and Hogan, ¿¿¿High Dose Ketoconazole For The Treatment Of Hormone Refractory Metastatic Prostate Carcinoma | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2021 Boumpas et al., ¿¿¿Glucocorticoid Therapy for Immune-mediated Diseases: Basic and Clinical Correlates,¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2022 Debruyne and Witjes, ¿¿¿Ketoconazole High Dose (H.D.) In The Management Of Metastatic Prostatic Carcinoma,¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2024 Krishnan et al., ¿¿¿A Glucocorticoid-Responsive Mutant Androgen Receptor Exhibits Unique Ligand | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
Conde and Aronson, ¿¿¿Risk factors for male osteoporosis,¿¿¿ Urologic Oncology, 21:380-383 (2003) | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2026 Remington ¿¿¿ The Science and Practice of Pharmacy, 20th ed., pp. 1363-1370 (2000) | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2027 Rumohr and Chang, ¿¿¿Current chemotherapeutic approaches for androgen-independent prostate cancer,¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2009 Garnick Deposition Ex. 1 ¿¿¿ Bubley et al., ¿¿¿Eligibility and Response Guidelines for Phase II Clinical Trials | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2010 Garnick Deposition Ex. 2 - 2015-12-04 Serels Declaration | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2012 Duc et al., ¿¿¿In vitro and in vivo models for the evaluation of potent inhibitors of male rat | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2014 Attard et al., ¿¿¿Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2015 Attard et al., ¿¿¿Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2019 Public Citizen Press Room Release ¿¿¿ ¿¿¿Antifunal Treatment Should Be Taken Off the Market, Public Citizen Tells FDAD,¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2020 Williams et al., ¿¿¿Objective Responses to Ketoconazole Therapy in
Patients with Relapsed Progressive Prostatic Cancer,¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2023 Herr and Pfitzenmaier, ¿¿¿Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic
treatment and metastases,¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2029 Judson CV | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2030 Clinical Cancer Research Peer Review letter to Judson, dated May 12, 20032030 | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2031 Burgess and Roth, ¿¿¿Changing Perspectives of the Role of Chemotherapy in Advanced Prostate Cancer,¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2011 Part 1 Garnick Deposition Ex. 3 ¿¿¿ Blackhard, Letter to Editor, J. Urology, 146(6):1621-1622 (1991) | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2033 Press Release 1/26/2016 | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2036 Hadaschik et al., ¿¿¿Novel targets and approaches in advanced prostate cancer,¿¿¿ Current Opinions Urology, 17:182-187 (2007) | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2028 Declaration of Professor Ian Judson, M.D | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2011 Part 2 Garnick Deposition Ex. 3 ¿¿¿ Blackhard, Letter to Editor, J. Urology, 146(6):1621-1622 (1991) | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2032 Strother et al., ¿¿¿Novel cytotoxic and biological agents for prostate cancer: Where will the money be in 2005?,¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2034 Press Release 1/21/2014 | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2035 Press Release 1/20/2015 | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2037 Deposition Transcript of Scott Serels, M.D., taken by Patent Owner on August 22, 2016 | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2038 Declaration of Matthew Rettig, M.D | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2040 Declaration of Richard Auchus, M.D., Ph.D. | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2042 Papatsoris et al., ¿¿¿Novel Biological Agents for the Treatment of Hormone-Refractory Prostate Cancer (HRPC),¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2043 Armstrong and Carducci, ¿¿¿New drugs in prostate cancer,¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2039 Rettig CV | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2041 Auchus CV | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2045 Vellturo CV | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2048 Altman et al., ¿¿¿The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration,¿¿¿ Ann. Intern. Med., 134:663-694 (2001) | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2055 Scher et al., ¿¿¿Bicalutamide for Advanced Prostate Cancer: The Natural Versus Treated History of Disease,¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2056 Sternberg, ¿¿¿Hormone refractory metastatic prostate cancer,¿¿¿ Annals of Oncology, 3:331-335 (1992) | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2058 Excerpts from Seifter, Concepts in Medical Physiology, Chapter 34, pp. 540-553, Chapter 37, pp. 606-620 (2005) | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2059 Petrylak et al., ¿¿¿Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer,¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2060 Marini et al., ¿¿¿The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer,¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2066 Mantero et al., ¿¿¿Long-term treatment of mineralocorticoid excess syndromes,¿¿¿ Steroids, 60:81-86 (1995)- | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2068 Swartz and Dluhy, ¿¿¿Corticosteroids: Clinical Pharmacology and Therapeutic Use,¿¿¿ Drugs, 16:238-255 (1978) | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2046 Therasse et al., ¿¿¿New Guidelines to Evaluate the Response to Treatment in Solid Tumors,¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2047 Stamey et al., ¿¿¿Prostate-Specific Antigen As A Serum Marker For Adenocarcinoma Of The Prostate,¿¿¿ NEJM, 317(15):909-916 (1987 | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2049 Blackard, ¿¿¿Letters to the Editor,¿¿¿ Journal of Urology, 146(6):1621-1622 (1991) | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2050 MedlinePlus, ¿¿¿ACTH stimulation test,¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2051 Dorin et al., ¿¿¿Diagnosis of Adrenal Insufficiency,¿¿¿ Ann. Inern. Med., 139:194-204 (2003) | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2052 Grinspoon and Biller, ¿¿¿Clinical Review 62 Laboratory Assessment of Adrenal Insufficiency,¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2053 Lara and Meyers, ¿¿¿Treatment Options in Androgen-Independent Prostate Cancer,¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2054 Kuzel et al., ¿¿¿A Phase II Study of Continuous Infusion 5-Fluorouracil in Advanced Hormone Refractory Prostate Cancer,¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2057 Bubley et al., ¿¿¿Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2061 Body, ¿¿¿Low-dose prednisone and increased risk of development of bone metastases,¿¿¿ Annals of Oncology, 7:643-645 (1996) | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2062 Craft, ¿¿¿Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure,¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2063 Small et al., ¿¿¿Antiandrogen Withdrawal Alone or in Combination With Ketoconazole in Androgen-Independent Prostate Cancer Patients: A Phase III Trial (CALGB 9583),¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2064 Millikan, et al., ¿¿¿Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer,¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2065 Farwell, et al., ¿¿¿Total Suppression of Cortisol Excretion by Ketoconazole in the Therapy of the Ectopic Adrenocorticotropic Hormone Syndrome,¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2067 Palmer, ¿¿¿Managing Hyperkalemia Caused by Inhibitors of the Renin¿¿¿Angiotensin¿¿¿Aldosterone System,¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2070 FDA Press Release (2011) | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2074 Active/Ipsen April 16, 2015 Press Release | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2076 Michaelson et al., ¿¿¿Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2081 Genentech March 12, 2010 Press Release | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2083 Novacea Form 8-K at 1.02 | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2084 ImmunoGen, Inc. Form 8-K, Item 8.01 | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2086 White, P.C., ¿¿¿Synthesis and Metabolism of Corticosteroids,¿¿¿ Principles and Practice of Endocrinology | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2089 NCI - SEER Stat Fact Sheets: Prostate Cancer | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2090 Tucker et al., ¿¿¿Reversible Adrenal Insufficiency Induced by Ketoconazole,¿¿¿ JAMA, 253(16):2413-2414 (1985) | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2069 Seale and Compton, ¿¿¿Side-effects of corticosteroid agents,¿¿¿, Med. J. of Australia, 144(3):139-142 (1986) | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2071 Ryan et al., ¿¿¿Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302) | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2072 Booth et al., ¿¿¿Oncology¿¿¿s trials,¿¿¿ Nature Reviews, 2:609-610 (2003) | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2073 Tokai July 26, 2016 Press Release | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2075 Takeda June 19, 2014 Press Release | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2077 OncoGenex (April 28, 2014) Press Release | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2078 BMS Sept. 12, 2013 Press Release | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2079 Carducci et al., ¿¿¿A Phase 3 Randomized Controlled Trial of the Efficacy and Safety of Atrasentan in Men With Metastatic Hormone-refractory Prostate Cancer,¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2080 Antonarakis and Eisenberger, ¿¿¿Phase III Trials With Docetaxel-Based Combinations for Metastatic Castration-Resistant Prostate Cancer: Time to Learn From Past Experiences,¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2082 Mulcahy, Medscape October 17, 2008 Press Release | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2085 Sephton, et al., ¿¿¿Diurnal Cortisol Rhythm as a Predictor of Breast Cancer Survival,¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2087 White, P.C., ¿¿¿Synthesis and Metabolism of Corticosteroids,¿¿¿ Principles and Practice of Endocrinology and Metabolism, | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2088 White, P.C., ¿¿¿Synthesis and Metabolism of Corticosteroids,¿¿¿ Principles and Practice of Endocrinology and Metabolism | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2095 Zytiga Usage ¿¿¿ prednisone information | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2098 ACS ¿¿¿ ¿¿¿What is Prostate Cancer? Topics¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2099 Cancer.Net - September 8, 2014 ¿¿¿Treatment of Metastatic Castration Resistant Prostate Cancer¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2091 What You Need to Know About Prostate Cancer, NIH Publication No. 12-1576 (2012) | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2096 Zytiga Usage ¿¿¿ total promotional spend | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2100 CDC ¿¿¿ ¿¿¿Prostate Cancer¿¿¿ | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2103 Medical Dictionary ¿¿¿ refractory cancer | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2106 Orange Book ¿¿¿ Xofigo | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2108 Orange Book ¿¿¿ Jevtana | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2109 Hotte and Saad, ¿¿¿Current management of castrate-resistant prostate cancer,¿¿¿ Current Oncology, 17(2):S72-S79 (2010) | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2116 Williams, ¿¿¿Discontinued Drugs in 2007: oncology drugs,¿¿¿ Expert Opinion on Investigational Drugs, 17(12):1791-1816 (2008) | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2117 Williams, ¿¿¿Discontinued Drugs in 2008: oncology drugs,¿¿¿ Expert Opinion on Investigational Drugs, 18(11):1581-1594 (2009) | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2101 J&J May 21, 2009 Press Release | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2102 Mayo Clinic ¿¿¿ Prednisone and other corticosteroids | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2104 NCI ¿¿¿ Docetaxel | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2105 NCI ¿¿¿ Metastatic Cancer | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2107 Orange Book ¿¿¿ Xtandi | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2110 J&J January 22, 2013 Press Release ¿¿¿ Johnson & Johnson Reports 2012 Fourth-Quarter and Full-Year Results | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2115 Redacted Expert Report of Christopher Vellturo | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2122 Declaration of Scott Serels, MD, filed on Jan. 16, 2017 in Amerigen Pharmaceuticals Ltd. v. Janssen Oncology, Inc., IPR2016-00286. | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2124 Deposition Transcript of Mark J. Ratain, M.D., taken by Patent Owner on January 23, 2017 in Amerigen Pharmaceuticals Ltd. v. Janssen Oncology, Inc., IPR2016-00286. | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2125 Deposition Transcript of Richard Dorin, M.D., taken by Patent Owner on January 19, 2017 in Amerigen Pharmaceuticals Ltd. v. Janssen Oncology, Inc., IPR2016-00286 | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2120 Declaration of Scott Serels, MD, filed on Dec. 4, 2015 in Amerigen Pharmaceuticals Ltd. v. Janssen Oncology, Inc., IPR2016-00286 | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2128 Deposition Transcript of Ivan T. Hofmann, taken by Patent Owner on February 7, 2017 | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2130 Academy of Managed Care Pharmacy (AMCP) Nexus 2016 Poster | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2131 Van den Akker et al., ¿¿¿Differential Inhibition of 17a-Hydroxylase and 17,20-Lyase Activities by Three Novel Missense CYP17 | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2133 Ryan, et al., ¿¿¿Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2134 ZYTIGA Market Share data | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2135 Truven Commercial and Medicare Data | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2126 Deposition Transcript of Marc b. Garnick, M.D., taken by Patent Owner on February 16, 2017 | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2127 Deposition Transcript of Scott R. Serels, taken by Patent Owner on January 21, 2017 in Amerigen Pharmaceuticals Ltd. v. Janssen Oncology, Inc., IPR2016-00286. | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2129 Eplerenone Label | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2132 Order Granting Janssen¿¿¿s Motion to Set a Hearing and Correct Inventorship | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2136 BTG Webpage from WayBack Machine | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2137 BTG Annual Report, 2003 | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2139 J&J Q1 2013 Earnings Call Transcript | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2142 J&J Q4 2013 Earnings Call Transcript | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2138 BTG Annual Report, 2004 | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2140 J&J Q2 2013 Earnings Call Transcript | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2141 J&J Q3 2013 Earnings Call Transcript | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2143 J&J Q1 2014 Earnings Call Transcript | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2144 J&J Q2 2014 Earnings Call Transcript | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2148 J&J Q2 2015 Earnings Call Transcript | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2145 J&J Q3 2014 Earnings Call Transcript | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2146 J&J Q4 2014 Earnings Call Transcript | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2147 J&J Q1 2015 Earnings Call Transcript | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2149 J&J Q3 2015 Earnings Call Transcript | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2150 IMS Health Data | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2151 2016-10-04 (Paper 33) Patent Owner Response in IPR2016-00286 | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
JSN 2152 Declaration of Bindu Donovan | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
Patent Owner's Response | Mar 8, 2017 | PAPER | PATENT OWNER |
Janssen Oncology, Inc.¿¿¿s Updated Exhibit List | Mar 8, 2017 | PAPER | PATENT OWNER |
EXPUNGED | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 8, 2017 | EXHIBIT | PATENT OWNER |
Patent Owners Notice of Deposition of Marc B. Garnick, M.D. | Feb 13, 2017 | PAPER | PATENT OWNER |
EXPUNGED | Feb 8, 2017 | PAPER | PETITIONER |
EXPUNGED | Feb 8, 2017 | EXHIBIT | PETITIONER |
EXPUNGED | Feb 8, 2017 | PAPER | PETITIONER |
EXPUNGED | Feb 8, 2017 | EXHIBIT | PETITIONER |
Joint Notice of Change to Due Date 1 | Feb 6, 2017 | PAPER | PATENT OWNER |
Patent Owners Notice of Deposition of Ivan T. Hofmann CPA/CFF, CLP | Feb 1, 2017 | PAPER | PATENT OWNER |
DECISION - Motion for Pro Hac Vice Admission | Jan 30, 2017 | PAPER | BOARD |
Patent Owner¿¿¿s Notice of Designation of Additional Backup Counsel | Jan 27, 2017 | PAPER | PATENT OWNER |
Janssen Oncology, Inc.¿¿¿s Updated Mandatory Notices | Jan 27, 2017 | PAPER | PATENT OWNER |
Patent Owners Objections to Evidence Pursuant to 37 C.F.R. 42.64(b)(1) | Jan 25, 2017 | PAPER | PATENT OWNER |
Motion for Pro Hac Vice Admission of Bryan D. Beel | Jan 25, 2017 | PAPER | PETITIONER |
Declaration of Bryan Beel | Jan 25, 2017 | EXHIBIT | PETITIONER |
Petitioner's Updated Exhibit List | Jan 25, 2017 | PAPER | PETITIONER |
Trial Instituted Document | Jan 10, 2017 | PAPER | BOARD |
Scheduling Order | Jan 10, 2017 | PAPER | BOARD |
2016/11/10 (DI 239)-Opinion on Markman Patent Claim Construction (DNJ) | Dec 19, 2016 | EXHIBIT | PATENT OWNER |
2016/14/10 (DI 240)-Order on Markman Patent Claim Construction (DNJ) | Dec 19, 2016 | EXHIBIT | PATENT OWNER |
Janssen Oncology, Inc.s Exhibit List | Dec 19, 2016 | PAPER | PATENT OWNER |
Order Conduct of the Proceeding | Dec 19, 2016 | PAPER | BOARD |
Pro Hac Vice Admission | Nov 4, 2016 | PAPER | BOARD |
Pro Hac Vice Admission | Nov 4, 2016 | PAPER | BOARD |
Conduct of the Proceeding | Oct 26, 2016 | PAPER | BOARD |
Janssen Oncologys Motion for Pro Hac Vice Admission of David T. Pritikin | Oct 12, 2016 | PAPER | PATENT OWNER |
Janssen Oncology, Inc.s Motion for Pro Hac Vice Admission of Bindu Donovan | Oct 12, 2016 | PAPER | PATENT OWNER |
JSN 2003 Bindu Donovan in Support of Motion to Appear Pro Hac Vice | Oct 12, 2016 | EXHIBIT | PATENT OWNER |
JSN 2002 Declaration David T. Pritikin in Support of to Appear Pro Hac Vice | Oct 12, 2016 | EXHIBIT | PATENT OWNER |
Janssen Oncology, Inc.s Preliminary Response | Oct 12, 2016 | PAPER | PATENT OWNER |
Janssen Oncology, Inc.s Updated Exhibit List | Oct 12, 2016 | PAPER | PATENT OWNER |
Order - Conduct of the Proceeding | Aug 26, 2016 | PAPER | BOARD |
Mylan's Reply in Support of its Motion for Joinder | Aug 9, 2016 | PAPER | PETITIONER |
Janssen Oncology's Opposition to Motion for Joinder | Jul 29, 2016 | PAPER | PATENT OWNER |
Notice of Accord Filing Date | Jul 12, 2016 | PAPER | BOARD |
Janssen Oncology, Inc.¿¿¿s Mandatory Notices | Jul 12, 2016 | PAPER | PATENT OWNER |
Janssen Oncology, Inc.¿¿¿s Power of Attorney | Jul 12, 2016 | PAPER | PATENT OWNER |
Notice of Termination of Preprocessing of EX Parte Reexamination Request | Jul 12, 2016 | EXHIBIT | PATENT OWNER |
Petition for Inter Partes Review | Jun 30, 2016 | PAPER | PETITIONER |
Power of Attorney | Jun 30, 2016 | PAPER | PETITIONER |
Motion for Joinder | Jun 30, 2016 | PAPER | PETITIONER |
'438 Patent | Jun 30, 2016 | EXHIBIT | PETITIONER |
Garnick Declaration | Jun 30, 2016 | EXHIBIT | PETITIONER |
O'Donnell | Jun 30, 2016 | EXHIBIT | PETITIONER |
Gerber | Jun 30, 2016 | EXHIBIT | PETITIONER |
'213 Patent | Jun 30, 2016 | EXHIBIT | PETITIONER |
Tannock 1996 | Jun 30, 2016 | EXHIBIT | PETITIONER |
Feb. 3, 2012 Office Action | Jun 30, 2016 | EXHIBIT | PETITIONER |
July 3, 2012 Response | Jun 30, 2016 | EXHIBIT | PETITIONER |
Ryan 2013 | Jun 30, 2016 | EXHIBIT | PETITIONER |
Jan. 11, 2103 | Jun 30, 2016 | EXHIBIT | PETITIONER |
Mar. 4, 2013 Office Action | Jun 30, 2016 | EXHIBIT | PETITIONER |
June 4, 2013 Office Action | Jun 30, 2016 | EXHIBIT | PETITIONER |
July 3, 2012 Notice of Allowance | Jun 30, 2016 | EXHIBIT | PETITIONER |
Oct. 25, 2013 Notice of Allowance | Jun 30, 2016 | EXHIBIT | PETITIONER |
Feb. 11, 2014 Notice of Allowance | Jun 30, 2016 | EXHIBIT | PETITIONER |
June 2, 2014 Notice of Allowance | Jun 30, 2016 | EXHIBIT | PETITIONER |
Hoffman Declaration | Jun 30, 2016 | EXHIBIT | PETITIONER |
Zytiga 2011 Label | Jun 30, 2016 | EXHIBIT | PETITIONER |
Zytiga Brochure | Jun 30, 2016 | EXHIBIT | PETITIONER |
Harris 2002 | Jun 30, 2016 | EXHIBIT | PETITIONER |
Oh 2002 | Jun 30, 2016 | EXHIBIT | PETITIONER |
Tannock 2004 | Jun 30, 2016 | EXHIBIT | PETITIONER |
Attard 2005 | Jun 30, 2016 | EXHIBIT | PETITIONER |
Hellerstedt 2002 | Jun 30, 2016 | EXHIBIT | PETITIONER |
Harrison's Internal Medicine | Jun 30, 2016 | EXHIBIT | PETITIONER |
Auchus 2001 | Jun 30, 2016 | EXHIBIT | PETITIONER |
Costa-Santos 2004 | Jun 30, 2016 | EXHIBIT | PETITIONER |
Jebelirer | Jun 30, 2016 | EXHIBIT | PETITIONER |
'977 Patent | Jun 30, 2016 | EXHIBIT | PETITIONER |
FDA News Release | Jun 30, 2016 | EXHIBIT | PETITIONER |
Tannock 1989 | Jun 30, 2016 | EXHIBIT | PETITIONER |
Scher 2012 | Jun 30, 2016 | EXHIBIT | PETITIONER |
de Bono 2011 | Jun 30, 2016 | EXHIBIT | PETITIONER |
Orange Book Listing | Jun 30, 2016 | EXHIBIT | PETITIONER |
Initial Application | Jun 30, 2016 | EXHIBIT | PETITIONER |
Office Action | Jun 30, 2016 | EXHIBIT | PETITIONER |
Cancer.net | Jun 30, 2016 | EXHIBIT | PETITIONER |
Cancer.org | Jun 30, 2016 | EXHIBIT | PETITIONER |
FDA News Release | Jun 30, 2016 | EXHIBIT | PETITIONER |
FDA Website | Jun 30, 2016 | EXHIBIT | PETITIONER |
FDA Website | Jun 30, 2016 | EXHIBIT | PETITIONER |
Galderma Labs | Jun 30, 2016 | EXHIBIT | PETITIONER |
Jevtana Website | Jun 30, 2016 | EXHIBIT | PETITIONER |
Kirby | Jun 30, 2016 | EXHIBIT | PETITIONER |
Mayo Clinic | Jun 30, 2016 | EXHIBIT | PETITIONER |
Merck v Teva | Jun 30, 2016 | EXHIBIT | PETITIONER |
Murphy | Jun 30, 2016 | EXHIBIT | PETITIONER |
PMLive | Jun 30, 2016 | EXHIBIT | PETITIONER |
Syntex v Apotex | Jun 30, 2016 | EXHIBIT | PETITIONER |
Zytiga Brochure | Jun 30, 2016 | EXHIBIT | PETITIONER |
Zytiga Label | Jun 30, 2016 | EXHIBIT | PETITIONER |
Zytiga Website | Jun 30, 2016 | EXHIBIT | PETITIONER |
Nov. 25, 2011 Office Action | Jun 30, 2016 | EXHIBIT | PETITIONER |
Dec. 21, 2011 | Jun 30, 2016 | EXHIBIT | PETITIONER |
Sept. 11, 2012 Office Action | Jun 30, 2016 | EXHIBIT | PETITIONER |
Oct. 3, 2013 IDS | Jun 30, 2016 | EXHIBIT | PETITIONER |
Oct. 3, 2013 IDS | Jun 30, 2016 | EXHIBIT | PETITIONER |
Jan. 10, 2014 IDS | Jun 30, 2016 | EXHIBIT | PETITIONER |
May 9, 2014 IDS | Jun 30, 2016 | EXHIBIT | PETITIONER |
May 9, 2014 IDS | Jun 30, 2016 | EXHIBIT | PETITIONER |
May 30, 2014 IDS | Jun 30, 2016 | EXHIBIT | PETITIONER |
May 30, 2014 IDS | Jun 30, 2016 | EXHIBIT | PETITIONER |
Barrie 1994 | Jun 30, 2016 | EXHIBIT | PETITIONER |
Fakih 2002 | Jun 30, 2016 | EXHIBIT | PETITIONER |
Lam 2006 | Jun 30, 2016 | EXHIBIT | PETITIONER |